Clinical Research Directory

AI Multimodal Model for Predicting CRPC Progression Risk

This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.